Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Recommendation of “Hold” from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given a consensus recommendation of “Hold” by the seven analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $3.75.

HOWL has been the topic of several analyst reports. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Friday, December 19th. HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. Finally, Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $0.66 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The business’s 50 day simple moving average is $0.66 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $32.04 million, a P/E ratio of -0.41 and a beta of 0.77.

Insider Activity

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total transaction of $80,733.10. Following the completion of the transaction, the insider owned 4,784,111 shares in the company, valued at $4,640,587.67. This represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $0.61, for a total value of $66,249.66. Following the completion of the sale, the director directly owned 2,550,674 shares of the company’s stock, valued at $1,555,911.14. The trade was a 4.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,811,009 shares of company stock valued at $1,496,837. Company insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Regal Investment Advisors LLC raised its stake in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the period. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Susquehanna International Group LLP lifted its stake in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.